Beta Bionics, Inc.
BBNX Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$19.16
KIRA · Stoqly’s AI analyst, in plain words
- Beta Bionics, Inc. had $100M of revenue in fiscal 2025, up 53.9% on the year before.
- Its operating margin was −71.5%, down 2.0 pts: of every 100 in sales, about −72 is left after running the business.
- Beta Bionics, Inc. lost $73.2M in fiscal 2025.
- Free cash flow was −$56.2M in fiscal 2025, −56.1% of revenue.
Market cap
$853M
P/E
—
Revenue
$100M
Net income
−$73.2M
Free cash flow
−$56.2M
Operating margin
−71.5%
Beta Bionics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+53.9%
Yes. Sales grew 53.9% last year.
Does it make a profit?
−73.0%
No. It lost money last year.
Does profit turn into cash?
−56.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Beta Bionics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- Beta Bionics, Inc.
- CIK
- 0001674632
Beta Bionics, Inc. · BBNX
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $12.0M | $65.1M | $100M |
| Revenue growth | — | 442.9% | 53.9% |
| Gross margin | 52.6% | 55.1% | 55.4% |
| Operating margin | −298.9% | −69.5% | −71.5% |
| Net income | −$44.1M | −$54.8M | −$73.2M |
| Net margin | −367.6% | −84.1% | −73.0% |
| Diluted EPS | −$8.31 | −$8.60 | −$1.81 |
| Cash | |||
| Cash from operations | −$32.4M | −$48.3M | −$50.9M |
| Capital expenditure | $0.4M | $3.4M | $5.3M |
| Free cash flow | −$32.8M | −$51.7M | −$56.2M |
| FCF margin | −273.8% | −79.3% | −56.1% |
| Share count change | — | 20.0% | 536.7% |
| Debt and strength | |||
| Cash and short-term investments | $96.7M | $104M | $219M |
| Shareholders' equity | −$203M | −$245M | $288M |
| Current ratio | 9.8x | 6.3x | 8.7x |
| Returns and quality | |||
| Return on equity | — | — | −346.5% |
| Return on tangible equity | — | — | −25.5% |
| Piotroski F-score | — | 4 | 4 |
| Altman Z'' | −7.6 | −7.1 | 6.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$4.6M
8 insiders
Of sales under plans
68%
$3.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Beta Bionics, Inc. · BBNX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $19.16 a share, the company is worth $853M.
Source: SEC EDGAR XBRL filings (CIK 0001674632). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.